Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma - Results from a prospective interventional case series

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 251, Issue 10, 2013, Pages 2403-2413

  Lüke, Julia ^a   Nassar, Khaled ^a   Lüke, Matthias ^a   Grisanti, Salvatore ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Lucentis; Neovascular glaucoma; Ranibizumab; Rubeosis; Treatment

Indexed keywords

RANIBIZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ANTERIOR EYE CHAMBER ANGLE; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; IRIS RUBEOSIS; LASER COAGULATION; MALE; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; VISUAL ACUITY; VITRECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIHYPERTENSIVE AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FLUOROPHOTOMETRY; GLAUCOMA, NEOVASCULAR; GONIOSCOPY; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; IRIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84890567423     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2428-y     Document Type: Article

References (24)

1. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352-354
2. Davidorf FH, Mouser JG, Derick RJ (2006) Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26:354-356
3. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group (2006) Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142:158-160
4. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142:1054-1056
5. Kahook MY, Schuman JS, Noecker RJ (2006) Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 37:144-146
6. Mason JO 3rd, Albert MA Jr, Mays A, Vail R (2006) Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26:839-841
7. Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU (2006) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84:556-557
8. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
9. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, ranodmized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399-2405
10. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A, RESTORE study group (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615-662
11. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE Investigators (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124-1133
12. Ehrenberg M, McCuen BW 2nd, Schindler RH, Machemer R (1984) Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology 91:321-325
13. Jaissle GB, Szurman P, Bartz-Schmidt KU (2005) [Recommendation for the implementation fo intravitreal injections - statement of the German Retina Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 222:390-395
14. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102-1112
15. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y (2008) Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115:1571-1580
16. Yazdani S, Hendi K, Pakravan M (2007) Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 16:437-439
17. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W (2008) Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 28:696-702
18. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R (2009) Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147:298-306
19. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, Stene-Johansen I (2010) Efficacy of ranibizumab in patients with macular edema secondary to central retinale vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 150:310-314
20. Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315-324
21. Campochiaro PA, Hadiz G, Channa R, Shah SM, Nguyen QD, Ying H, Do DV, Zimmer-Galler I, Solomon SD, Sung JU, Syed B (2010) Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology 117:2387-2394
22. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D'Amore PA, Shima DT, Adamis AP (2003) VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198:483-489
23. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48:1773-1781
24. Martin DF, Maguire MG, Fine SL, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Comparison of age-related macular degeneration treatments trials (CATT) research group writing committee: ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388-1398